Skip to main content

Latest news

Neuer Inhalt Free registration

Gain full access to the latest clinical content available from Springer Nature

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by

Type 2 diabetes

Canagliflozin benefits may extend to primary prevention

Cardiovascular general

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

Latest headlines

11-17-2017 | Primary care | News

Care delivery variation affects glycemic control for type 1 diabetes patients

If all UK primary care practices operated to the standards of the top-performing centers there would be a marked nationwide increase in the proportion of patients with type 1 diabetes achieving glycemic control, say researchers.


Diabet Med 2017; Advance online publication

11-16-2017 | Cardiovascular disorders | News

Coronary artery calcification predicts CVD risk regardless of diabetes status

Results of a multiethnic cohort study suggest that coronary artery calcium scoring can predict long-term cardiovascular risk in patients with and without metabolic abnormalities.


JAMA Cardiol 2017; Advance online publication

11-15-2017 | Neuropathy | News

Spinal cord stimulation efficacy sustained in patients with diabetic polyneuropathy

Patients with painful diabetic polyneuropathy continue to experience pain relief in the lower extremities for at least 5 years of spinal cord stimulation, suggest study findings.


Diabetes Care 2017; Advance online publication

11-14-2017 | Glycemic control | News

News in brief

Improvements in glycemic control may have stagnated

Data from the US NHANES surveys show no improvements in glycemic control over recent years, despite greater patient awareness of their test results and glycated hemoglobin targets.

In depth

Metabolically healthy obesity: Laying a controversial concept to rest

The concept of metabolically healthy obesity has produced huge numbers of seemingly contradictory studies, and polarized opinion among researchers. medwireNews looks back at the big data, the high-impact publications, and the underlying hypotheses that helped the concept to persist for so long, and asks if the field has finally reached consensus.

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

SGLT2 inhibitors: The story so far

Editorial board member John Wilding discusses the lessons for healthcare professionals from the SGLT2 inhibitor cardiovascular outcome trials about the benefits and drawbacks of the medication class.

image credits